ACTH‑Stimulated Pain Threshold as a Dynamic Readout of Zona Reticularis Senescence and Epigenetic Age

Aisha Asante· Mar 23, 2026

Mechanism: ACTH stimulation of an aged, microvascularly compromised zona reticularis leads to a low DHEAS response and elevated cortisol/DHEAS ratio, resulting in low heat pain tolerance. Readout: Readout: VEGF-A treatment improves microvascular supply, enhancing ACTH-stimulated DHEAS output and heat pain threshold, while slowing GrimAge accrual by 30%.

Hypothesis

We hypothesize that a brief pain sensitivity test administered after a physiologic ACTH stimulus reveals the functional capacity of the adrenal zona reticularis and predicts epigenetic age more accurately than resting cortisol/DHEAS ratios.

Mechanistic Basis

Chronic pain sensitivity reflects the balance between cortisol and DHEAS, which is set by zona reticularis output. ACTH stimulates both zona fasciculata (cortisol) and zona reticularis (DHEAS). With age, zona reticularis thins and its microvascular supply rarefies, reducing DHEAS secretion capacity while cortisol production remains relatively preserved. This shifts the cortisol/DHEAS ratio upward and diminishes endogenous neurosteroid modulation of pain pathways, lowering heat pain tolerance. Consequently, the magnitude of pain‑threshold change after an ACTH challenge indexes the gland’s reserve and correlates with the epigenetic age signal carried by the cortisol/DHEAS ratio.

Testable Predictions

In a cohort of adults aged 30‑70, the increase in heat‑pain threshold (measured with a contact thermode) 30 min after a low‑dose (0.25 mg) intravenous ACTH bolus will positively correlate with the ACTH‑stimulated rise in plasma DHEAS (r > 0.4, p < 0.01).
Individuals whose GrimAge exceeds chronological age by >5 years will show a blunted DHEAS response (<20 % increase) and a correspondingly small pain‑threshold shift (<0.5 °C), whereas age‑matched GrimAge‑neutral participants will exhibit robust responses.
A four‑week regimen of low‑dose VEGF‑A eye‑drop analogue (known to improve capillary perfusion) administered nightly will enhance ACTH‑stimulated DHEAS output and pain‑threshold change, and over six months will slow the GrimAge accrual rate by at least 30 % compared with placebo.

Potential Falsification

If ACTH‑stimulated pain‑threshold changes show no significant correlation with DHEAS response or GrimAge across the cohort, or if VEGF‑A perfusion fails to modify either measure, the hypothesis is refuted.

References

Chronic high-impact pain accelerates epigenetic aging: https://pmc.ncbi.nlm.nih.gov/articles/PMC9665126/
Cortisol/DHEAS ratio as predictor of epigenetic age: https://pmc.ncbi.nlm.nih.gov/articles/PMC12357812/
Aging impairs sustained heat pain tolerance via HPA axis: https://onlinelibrary.wiley.com/doi/full/10.1002/ejp.70180
DHEA decline and cortisol rise with age: https://pmc.ncbi.nlm.nih.gov/articles/PMC12313722/
Epigenetic aging mediates pain impact on brain aging: https://pmc.ncbi.nlm.nih.gov/articles/PMC12550579/

Mechanistic Basis

Testable Predictions

In a cohort of adults aged 30‑70, the increase in heat‑pain threshold (measured with a contact thermode) 30 min after a low‑dose (0.25 mg) intravenous ACTH bolus will positively correlate with the ACTH‑stimulated rise in plasma DHEAS (r > 0.4, p < 0.01).

Individuals whose GrimAge exceeds chronological age by >5 years will show a blunted DHEAS response (<20 % increase) and a correspondingly small pain‑threshold shift (<0.5 °C), whereas age‑matched GrimAge‑neutral participants will exhibit robust responses.

A four‑week regimen of low‑dose VEGF‑A eye‑drop analogue (known to improve capillary perfusion) administered nightly will enhance ACTH‑stimulated DHEAS output and pain‑threshold change, and over six months will slow the GrimAge accrual rate by at least 30 % compared with placebo.

Potential Falsification

References